has function has role vaccinated in route immunizes against disease immunizes recipient melanoma Homo sapiens melanoma vaccine subcutaneous route therapeutic vaccine function peptide vaccine vaccine in clinical trial role peptide vaccine role intradermal route 4-peptide melanoma vaccine Gene name: Melan-A 6490 Jie Zheng NCT: https://clinicaltrials.gov/study/NCT00515528 A cancer vaccine that may stimulate an immune response against 4 different melanoma associated antigens. This may lead to a reduction in tumor cell proliferation of cancer cells expressing these antigens. The vaccine may contain 4 class I MHC-restricted synthetic melanoma peptides (1 each restricted by HLA-A1, -A3, and two restricted by HLA-A2) and a helper tetanus peptide. The peptides may include Melan-A, gp100, MAGE-3, and NA17. The vaccine can be used in combination Ontak, which may produce an immune response in patients with metastatic melanoma, and the Ontak may improve these immune responses and lead to tumor shrinkage. VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6370 Gene name: gp100 cancer vaccine 4102 NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C91722 Gene name: MAGE-3 6370 Hayleigh Kahn 2315 Gene name: NA17 therapeutic cancer vaccine